Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial

ObjectiveTo assess the incremental cost and cost-effectiveness of a restrictive versus a liberal red blood cell transfusion threshold after cardiac surgery.DesignA within-trial cost-effectiveness analysis with a 3-month time horizon, based on a multicentre superiority randomised controlled trial fro...

Full description

Saved in:

Bibliographic Details
Published in:	BMJ open 2016-07, Vol.6 (8), p.e011311-e011311
Main Authors:	Stokes, E A, Wordsworth, S, Bargo, D, Pike, K, Rogers, C A, Brierley, R C M, Angelini, G D, Murphy, G J, Reeves, B C
Format:	Article
Language:	eng
Subjects:	Aged Anemia Anemia - blood Anemia - etiology Anemia - therapy Blood products Cardiac Surgical Procedures - adverse effects Cardiovascular Medicine Community health care Cost analysis Cost-Benefit Analysis Erythrocyte Transfusion - economics Erythrocytes Female Health services Heart surgery Hemoglobins - metabolism Hospital Costs Hospitalization Hospitals Humans Male Patients Postoperative Complications - economics Postoperative Complications - therapy Quality of Life Quality-Adjusted Life Years State Medicine United Kingdom
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ObjectiveTo assess the incremental cost and cost-effectiveness of a restrictive versus a liberal red blood cell transfusion threshold after cardiac surgery.DesignA within-trial cost-effectiveness analysis with a 3-month time horizon, based on a multicentre superiority randomised controlled trial from the perspective of the National Health Service (NHS) and personal social services in the UK.Setting17 specialist cardiac surgery centres in UK NHS hospitals.Participants2003 patients aged >16 years undergoing non-emergency cardiac surgery with a postoperative haemoglobin of
ISSN:	2044-6055 2044-6055